國立虎尾科技大學 |

Combination Therapy In Dyslipidemia

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Combination Therapy In Dyslipidemia/ edited by Maciej Banach.
其他作者:	Banach, Maciej.
面頁冊數:	VIII, 205 p. 22 illus., 15 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cardiology. -
電子資源:	https://doi.org/10.1007/978-3-319-20433-8
ISBN:	9783319204338

Combination Therapy In Dyslipidemia
Combination Therapy In Dyslipidemia[electronic resource] /edited by Maciej Banach. - 1st ed. 2015. - VIII, 205 p. 22 illus., 15 illus. in color.online resource.

Foreword -- Statins and bile acid resins – is there a place for such a combination? -- Statins and fibrates – should it be recommended? -- Statins and ezetimibe – doubts or bright future? -- Statins and niacin – the end of residual risk therapy? -- Statins and omega-3 fatty acids – what more do we need? -- Statins and CETP inhibitors – anacetrapib and evacetrapib – the last hope? -- Statins and mipomersen – the issue of tolerability? -- Statins and lomitapide – a suitable response for HoFH -- Statins and PCSK9 inhibitors – defining the correct patients -- Other possible drug combination for dyslipidaemia -- Statins and nutraceuticals/functional food – Could be they combined? -- Lipid lowering therapy and apheresis – indications and outcomes -- Combination of lipid lowering agents with antihypertensive drugs – a joint fight against the two most important risk factors? -- Not only dyslipidaemia therapy – the time for polypills -- Drug Evaluation: Fenofibrate + simvastatin for the treatment of dyslipidemia: When and for whom? -- Drug Evaluation: Olmesartan medoxomil + rosuvastatin for the treatment of dyslipidemia and concomitant risk factors: A chance for better compliance? -- Conclusions and Take Home Message.

Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP), and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.

ISBN: 9783319204338

Standard No.: 10.1007/978-3-319-20433-8doiSubjects--Topical Terms:

593957
Cardiology.

LC Class. No.: RC681-688.2

Dewey Class. No.: 616.12

Combination Therapy In Dyslipidemia
LDR:04108nam a22003975i 4500 001 965350
003 DE-He213
005 20200705235010.0
007 cr nn 008mamaa
008 201211s2015 gw | s |||| 0|eng d
020 $a 9783319204338 $9 978-3-319-20433-8
024 7 $a 10.1007/978-3-319-20433-8 $2 doi
035 $a 978-3-319-20433-8
050 4 $a RC681-688.2
072 7 $a MJD $2 bicssc
072 7 $a MED010000 $2 bisacsh
072 7 $a MJD $2 thema
082 0 4 $a 616.12 $2 23
245 1 0 $a Combination Therapy In Dyslipidemia $h [electronic resource] / $c edited by Maciej Banach.
250 $a 1st ed. 2015.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2015.
300 $a VIII, 205 p. 22 illus., 15 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Foreword -- Statins and bile acid resins – is there a place for such a combination? -- Statins and fibrates – should it be recommended? -- Statins and ezetimibe – doubts or bright future? -- Statins and niacin – the end of residual risk therapy? -- Statins and omega-3 fatty acids – what more do we need? -- Statins and CETP inhibitors – anacetrapib and evacetrapib – the last hope? -- Statins and mipomersen – the issue of tolerability? -- Statins and lomitapide – a suitable response for HoFH -- Statins and PCSK9 inhibitors – defining the correct patients -- Other possible drug combination for dyslipidaemia -- Statins and nutraceuticals/functional food – Could be they combined? -- Lipid lowering therapy and apheresis – indications and outcomes -- Combination of lipid lowering agents with antihypertensive drugs – a joint fight against the two most important risk factors? -- Not only dyslipidaemia therapy – the time for polypills -- Drug Evaluation: Fenofibrate + simvastatin for the treatment of dyslipidemia: When and for whom? -- Drug Evaluation: Olmesartan medoxomil + rosuvastatin for the treatment of dyslipidemia and concomitant risk factors: A chance for better compliance? -- Conclusions and Take Home Message.
520 $a Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP), and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.
650 0 $a Cardiology. $3 593957
650 0 $a Pharmacotherapy. $3 973587
650 0 $a Pharmacology. $3 583819
650 2 4 $a Pharmacology/Toxicology. $3 593882
700 1 $a Banach, Maciej. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1260927
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319204345
776 0 8 $i Printed edition: $z 9783319204321
776 0 8 $i Printed edition: $z 9783319367217
856 4 0 $u https://doi.org/10.1007/978-3-319-20433-8
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)